Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05014139 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT05014139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05014139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 7, 2021
Completion date
September 22, 2025
Enrollment
37 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma in situ, carcinoma transitional cell, nmibc, non-muscle invasive bladder cancer, urinary bladder neoplasms